Please assess the completion status of the following clinical trial:

Trial Title: Cancer Venous Thromboembolism (VTE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with age ≥ 18 years or the otherwise legal lower age according to the country of residence;~* Confirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated;~* Cancer, other than basal-cell or squamous-cell carcinoma of the skin;~* Able to provide written informed consent.~Exclusion Criteria:~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE;~* Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization;~* Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban;~* Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban group (Type: EXPERIMENTAL): After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
- Dalteparin group (Type: ACTIVE_COMPARATOR): Participants receive Dalteparin treatment daily -solution for subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).